Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 1.00 |
| ▸ | F2 | P00734 | 12/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 10/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 9/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 9/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.76 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.72 |
| ▸ | F9 | P00740 | 2/20 | 0.69 |
| ▸ | PROC | P04070 | 2/20 | 0.69 |
| ▸ | KLK1 | P06870 | 1/20 | 0.69 |
| ▸ | CFH | P08603 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13550922 | 0.89 | F10 (1.00) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3832849 | 0.89 | F2 (0.79) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL14542915 | 0.87 | F10 (1.00) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3836169 | 0.84 | F10 (0.73) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7749603 | 0.84 | PRSS1 (0.88) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL8169448 | 0.83 | F10 (1.00) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL28111188 | 0.82 | KLKB1 (0.83) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7742478 | 0.82 | F10 (0.89) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL3052253 | 0.82 | F10 (1.00) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL31067656 | 0.82 | F10 (1.00) | F10F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794412-B1 | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-21 | — | — | US | disclosed |
| US-6794412-B1 | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-21 | — | — | US | disclosed |